US-based CenExel Clinical Research has announced the creation of its Centers of Excellence company to execute Phase I-IV trials.
The Centers of Excellence company will combine four experienced clinical research units in the country for designing and executing the trials, including Phase I studies in patients.
They are aimed at helping pharmaceutical companies improve the time and cost of new therapy development for better patient care.
CenExel operates advanced facilities in Utah, California, Georgia and Maryland. The facilities are used for conducting clinical trials with experienced staff.
All the firms involved in the company are recognised as one of the trusted research facilities in their respective fields such as post-operative pain, central nervous system disorders, chronic disease management, and psychiatric illnesses.
CenExel CEO Tom Wardle said: “CenExel Centers of Excellence offer pharmaceutical companies and clinical research organisations access to some of the finest investigators and facilities in the world for conducting research.
“We are focused on delivering the highest possible quality through our combined expertise, the engagement of our investigators and staff, and most importantly, our results.”
CenExel, which was formed last year, is the result of the merger between JBR Clinical Research and ACMR, an Atlanta-based psychiatric research facility.
It aims to work with trial sponsors and CROs to reduce costs and development times for novel therapies advancing patient care.
CenExel Business Development and Integration vice-president Kevin Quinn said: “The level of engagement among staff and patients is a key differentiator with our Centers of Excellence.
“This commitment has enabled our Centers to routinely meet or exceed patient recruitment goals in hundreds of clinical trials, so we are able to complete studies on-time and within budget.”